Study record · Long R3 IGF-1
LongR3-IGF-I anti-doping analytical study and product-quality evidence
Authors state LongR3-IGF-I and related analogues were never approved for human use; black-market products showed oxidized/low-quality forms.
Key result
Authors state LongR3-IGF-I and related analogues were never approved for human use; black-market products showed oxidized/low-quality forms.
Study details
Study designAnalytical / anti-doping study
PopulationHuman serum matrices plus black-market product analysis; animal administration for detectability
RouteAnalytical / preclinical
Regimen / exposureLongR3-IGF-I and related analogues
DurationAnalytical validation
ComparatorNot applicable
Primary endpoint / questionRegulatory/use status and product identity
Safety resultDoes not provide a therapeutic human safety dataset.
Key limitationsAnalytical/detection evidence does not establish efficacy; product-quality findings may not apply to every source but demonstrate real market risk.
Registry / identifierPMID 33587816